Cai (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
https://doi.org/10.1016/j.eng.2020.03.007
https://www.sciencedirect.com/science/article/pii/S2095809920300631?via%3Dihub
Status
Time from onset to treatment (1 day increase vs. Not applicable)
Virus clearance
Hazard ratio: 1.217 (0.996-1.486) Adjusted model

China

Non-randomized clinical trial

Primary data collection

80

laboratory-confirmed COVID-19 patients

56 patients with laboratory-confirmed COVID-19 were screened, of which 35 were eligible for the FPV arm of the study. A total of 91 laboratory-confirmed COVID-19 patients who had started treatment with LPV/RTV between 24 January and 30 January 2020 were screened, of which 45 were eligible for the control arm of this study.

Total

14 Day


Virus clearance

0

A multivariate Cox regression model was used to explore the independent factors affecting viral clearance. The time of viral clearance was set as the TIME variable, viral clearance (0 = no, 1 = yes) was set as the status, and the variables that were significant (P < 0.10) in the univariate Cox analysis or were professionally significant (including age, and whether underlying diseases were present or not) were set as independent variable


Status

Time from onset to treatment

Time from onset to treatment

Not applicable

1 day increase


Hazard ratio

1.217 (0.996-1.486)

No

No

Yes

WBC. Hp, PLT, Neutrophils, T lymphocyte count , CD8+ T lymphocyte , Time from onset to treatment , FPV versus LPV/RTV , Age , Underlying diseases


none

Average

No